Sign in

You're signed outSign in or to get full access.

RI

REGENXBIO Inc. (RGNX)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 results beat consensus: revenue $29.73M vs $24.41M consensus and EPS $(1.20) vs $(1.34) consensus; both beats reflect incremental development service revenue and disciplined OpEx while interest expense from royalty monetization remained a headwind . Consensus from S&P Global: revenue $24.41M*, EPS $(1.34)* (9 ests each). Values retrieved from S&P Global.
  • Pipeline momentum: RGX‑202 pivotal enrollment completed in October; topline in early Q2 2026 and BLA mid‑2026; first commercial batches already produced in-house; capacity up to 2,500 doses/year .
  • RGX‑121 BLA review ongoing; PDUFA moved to Feb 8, 2026; FDA completed facility and site inspections with no observations; PRV expected upon approval .
  • AbbVie retinal franchise advancing: Subretinal wet AMD trials fully enrolled with topline expected in Q4 2026; DR pivotal (suprachoroidal) moving to Phase IIb/III with $100M milestone at first patient dosed; site selection in progress .
  • Liquidity: Cash, cash equivalents and marketable securities $302.0M; runway into early 2027, excluding potential milestones/PRV monetization—an important non-dilutive upside noted by management .

What Went Well and What Went Wrong

What Went Well

  • Completed key clinical milestones: “completed enrollment in the AFFINITY DUCHENNE Pivotal Trial… on track to share top‑line pivotal data in early Q2 2026… submit a BLA… mid‑2026” .
  • Manufacturing execution and scale: “produced the first batches of RGX‑202 intended for commercial supply… 2,000‑liter bioreactor… able to produce up to 2,500 doses per year” .
  • Regulatory readiness for RGX‑121: “FDA completed inspections of our clinical sites and in‑house manufacturing facility with no observations, a rare and significant achievement,” supporting confidence into the Feb 8, 2026 PDUFA .

What Went Wrong

  • Continued GAAP losses and higher financing costs: Net loss $(61.9)M; interest expense rose to $13.17M (linked to royalty monetization liabilities), pressuring bottom‑line despite higher revenue .
  • Dependence on accelerated approvals and external controls: Management emphasized significant functional benefit vs natural history for DMD to support accelerated approval; nevertheless, reliance on external controls remains a known regulatory debate .
  • Ex‑U.S. regulatory uncertainty: EMA feedback still favors placebo controls; company exploring name‑patient sales and evolving endpoints, adding potential timing/complexity outside the U.S. .

Financial Results

Summary P&L and Operating Metrics (GAAP)

MetricQ1 2025Q2 2025Q3 2025
Revenue ($M)$89.01 $21.36 $29.73
Total Operating Expenses ($M)$76.89 $84.64 $82.14
Net Income (Loss) ($M)$6.08 $(70.87) $(61.94)
Diluted EPS ($)$0.12 $(1.38) $(1.20)
Investment Income ($M)$2.50 $3.38 $3.62
Interest Expense ($M)$(8.57) $(10.99) $(13.17)

Segment Revenue Breakdown

Revenue Component ($M)Q1 2025Q2 2025Q3 2025
License & Royalty$87.05 $18.47 $23.61
Service Revenue$1.96 $2.89 $6.13
Total$89.01 $21.36 $29.73

Note: Q3 increase was “primarily attributable to $5.9M of development service revenue under the Nippon Shinyaku partnership” .

KPIs and Cash

KPIQ1 2025Q2 2025Q3 2025
Cash, Cash Equivalents & Marketable Securities ($M)$272.7 $363.6 $302.0
R&D Expense ($M)$53.09 $59.50 $56.10
G&A Expense ($M)$20.35 $19.88 $20.25
Cash Runway (mgmt)2H 2026 Early 2027 Early 2027

Q3 2025 vs. Estimates (S&P Global)

MetricActualConsensusSurprise
Revenue ($M)$29.73 $24.41*+$5.32 (Beat)
EPS ($)$(1.20) $(1.34)*+$0.14 (Beat)
# of Estimates—9*—

Values retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayCorporateEarly 2027 (Q2’25) Early 2027 (Q3’25) Maintained
RGX‑202 ToplineDuchenne1H 2026 (Q2’25) Early Q2 2026 Narrowed timing (more specific)
RGX‑202 BLADuchenneMid‑2026 Mid‑2026 Maintained
RGX‑121 PDUFAMPS IINov 9, 2025 (prior) Feb 8, 2026 Extended
ABBV‑RGX‑314 Topline (subretinal)Wet AMD2026 Q4 2026 Narrowed timing
DR Pivotal (suprachoroidal)DRInitiate Phase IIb/III; $100M at 1st Pt Dosed Site selection in progress Continuing execution

Earnings Call Themes & Trends

TopicQ1 2025 (Q‑2)Q2 2025 (Q‑1)Q3 2025 (Current)Trend
RGX‑202 (DMD) safety/efficacy, accelerated approval>50% pivotal enrollment; strong safety/functional signals; aim broad label Accelerated pivotal completion to Oct; proactive immune suppression highlighted Enrollment completed; significant improvement vs natural history; pre‑BLA around topline; leverage safety vs competitor Strengthening safety/efficacy narrative; advancing to filing
RGX‑121 (MPS II) regulatoryBLA submitted; acceptance expected; 2H’25 approval aimed Priority review; inspections with no observations PDUFA Feb 8, 2026; inspections “no observations”; late‑cycle mtg upcoming Timing extended; regulatory interactions positive
ABBV‑RGX‑314 (retina)Subretinal pivotal enrollment by 2025; DR pivotal planning DR Phase IIb/III + revised milestones; robust 2‑year NPDR data Subretinal enrollment completed; DR Phase IIb/III site selection; Q4’26 topline for wet AMD Execution progress; milestones to de‑risk funding
Manufacturing scale2,500 doses/yr target; initiate commercial supply H2’25 Initiating commercial manufacturing in fall First commercial batches produced; 2,000L bioreactor; 2,500 doses/yr Capacity realized ahead of launches
Cash/liquidity$272.7M; runway to 2H’26; non‑dilutive options $363.6M; runway to early 2027 $302.0M; runway to early 2027; PRV/milestones could extend beyond 2027 Stable runway; optionality reiterated
Ex‑U.S. pathways——EMA may prefer placebo control; consider name‑patient sales Ex‑U.S. strategy evolving

Management Commentary

  • “We completed enrollment in the AFFINITY DUCHENNE Pivotal Trial… on track to share top‑line pivotal data in early Q2 2026… submit a BLA… mid‑2026.”
  • “FDA completed inspections of our clinical sites and in‑house manufacturing facility with no observations, a rare and significant achievement.”
  • “The manufacturing facility… 2,000‑liter bioreactor… able to produce up to 2,500 doses of RGX‑202 per year… we can certainly inventory… to have a significant number of doses available at launch.”
  • On DR pivotal design: “Two‑part… double‑masked sham injection control trial… primary endpoint two‑step DRSS improvement,” with optionality to consider ordinal analysis under evolving FDA precedent .
  • Financial stance: “We expect the September 30th cash balance… to fund our operations into early 2027… non‑dilutive financing opportunities could further extend… well beyond 2027.”

Q&A Highlights

  • DMD accelerated approval and external controls: Company expects significant functional benefit vs matched natural history/external controls, supporting accelerated path; pre‑BLA meeting anticipated around topline; safety differentiation emphasized relative to class .
  • Confirmatory study: Open and enrolling; similar design (ambulatory, age ≥1), 30 additional patients; investigators and families showing strong enthusiasm .
  • EMA posture: Ex‑U.S. regulators may seek placebo controls; exploring name‑patient options meanwhile .
  • DR pivotal endpoints: Considering ordinal DRSS change per evolving FDA acceptance; sees strength in both two‑step improvement and reducing worsening/VTEs .
  • Manufacturing capacity and launch readiness: 2,000L scale; up to 2,500 RGX‑202 doses/year; MPS II uses <5% of capacity; inventory build ahead of launch .

Estimates Context

  • Q3 2025: Revenue $24.41M consensus (9 ests)* vs actual $29.73M; EPS $(1.34) consensus (9 ests)* vs actual $(1.20); both beats. Target price consensus mean $29.55 (11 ests)*. Values retrieved from S&P Global.
  • Implications: Consensus likely to drift upward on service revenue contribution (Nippon Shinyaku workstreams) and confidence in regulatory timelines; however, rising interest expense offsets may cap EPS revisions until milestone/PRV monetization materializes .

Key Takeaways for Investors

  • Near‑term catalysts: RGX‑121 PDUFA (Feb 8, 2026); DR Phase IIb/III first‑patient dose (triggers $100M); continued confirmatory enrollment for RGX‑202; subretinal wet AMD pivotal topline in Q4 2026 .
  • RGX‑202 de‑risking: Completed pivotal enrollment, compelling functional signals, and clean safety profile underpin an accelerated filing in mid‑2026; internal capacity supports rapid commercial scale .
  • Liquidity/optionality: $302.0M cash/securities and early‑2027 runway; PRV sale and AbbVie milestones could extend runway beyond 2027, reducing financing overhang .
  • Watch regulatory dynamics: FDA appears constructive (no‑observation inspections), but reliance on external controls and evolving EMA standards present pathway risk; confirmatory study progress mitigates .
  • Retina optionality: Subretinal program nearing readout in a large indication; DR pivotal design and milestones offer substantial strategic value and funding leverage with AbbVie .
  • Financial structure: Interest expense is rising from royalty monetization liabilities, pressuring EPS near‑term; stronger service revenue and potential milestones can offset .
  • Trading setup: Positive regulatory and pivotal‑stage execution, plus milestone visibility, set multiple binary catalysts over next 3–12 months; downside tied to regulatory timing, external‑control debates, and macro biotech risk .

Values retrieved from S&P Global.